Radius garners $57.5M in second round

Looking to advance drug candidates for osteoporosis and women's health in new clinical studies, Cambridge, MA-based Radius announced $57.5 million in new venture funding. The second round for Radius will be split in half, with the second half contingent on certain undisclosed conditions.

"Over the past three years, Radius has transitioned from a start-up to a leading clinical-stage women's healthcare company," said Ansbert Gadicke, MD, founding general partner of MPM Capital. Dr. Lyttle and his team have expanded the product portfolio to include drug candidates for osteoporosis and women's health.

- check out the release on the Radius round

ALSO: Denmark's Egalet has raised $19.27 million in its second round of venture capital. Vaekstfonden Life Science Ventures led the round with Atlas Venture, Bio Fund, Dansk Kapitalanlaeg, Danske Bank, Index Ventures and QueQuoin Holdings all taking part. Egalet has been using its technology for orally-released therapies to develop a pipeline of drugs for pain and cardiovascular uses. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.